1-6 of 6
Rebecca Auer, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genomic Profiling Reveals Spatial Intra-Tumor Heterogeneity in Follicular Lymphoma

Shamzah Araf, MRCP, MBBS, Jun Wang, PhD, Koorosh Korfi, PhD BSc, Celine Pangault, PhD, Eleni Kotsiou, PhD, Ana Rio-Machin, PhD, Tahrima Rahim, BSc, James Andrew Heward, PhD BSc, Andrew James Clear, BSc, Sameena Iqbal, Jeff Davies, MBBS, PhD, Peter Johnson, MD FRCP, Maria Calaminici, MD PhD, Silvia Montoto, Rebecca Auer, MD PhD, Claude Chelala, PhD, John G. Gribben, MDDSc FMedSci, Trevor Graham, PhD, Thierry Fest, MD PhD, Jude Fitzgibbon, PhD, Jessica Okosun, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2730.
https://doi.org/10.1182/blood.V130.Suppl_1.2730.2730
Published: 2017
Journal Articles

Median 3.5-Year Follow-up of Ibrutinib Treatment in Patients with Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis

Simon Rule, MD, Martin Dreyling, MD PhD, Andre Goy, MD, Georg Hess, Rebecca Auer, MD PhD, Brad S Kahl, MD, Jose Angel Hernandez-Rivas, Anil Londhe, PhD, Fong Clow, ScD, Sanjay Deshpande, Lori Parisi, Michael Wang, BS
Journal: Blood
Blood (2017) 130 (Supplement 1): 151.
https://doi.org/10.1182/blood.V130.Suppl_1.151.151
Published: 2017
Journal Articles

Single-Agent Ibrutinib Demonstrates Safety and Durability of Response at 2 Years Follow-up in Patients with Relapsed or Refractory Mantle Cell Lymphoma: Updated Results of an International, Multicenter, Open-Label Phase 2 Study

Michael Wang, MD, Simon Rule, MD, Peter Martin, MD, Andre Goy, MD, Rebecca Auer, MD PhD, Brad S. Kahl, MD, Wojciech Jurczak, Ranjana Advani, MD, Jorge E. Romaguera, MD, Michael E. Williams, MD, Jacqueline C. Barrientos, MD, Ewa Chmielowska, MD, John Radford, Stephan Stilgenbauer, MD, Martin Dreyling, Wieslaw Wiktor Jedrzejczak, MD, Peter W Johnson, MD, Stephen E. Spurgeon, MD, Liang Zhang, MD PhD, Linda Baher, Mei Cheng, PhD, Darrin M. Beaupre, MD, Kristie A. Blum, MD
Journal: Blood
Blood (2014) 124 (21): 4453.
https://doi.org/10.1182/blood.V124.21.4453.4453
Published: 2014
Journal Articles

Increased Tonic PI3K Signaling Through p110α Can Limit the Efficacy of P110δ-Selective Inhibition in Mantle Cell Lymphoma, Particularly with Multiple Relapse

Sunil Iyengar, MD, Andrew James Clear, BSc, Csaba Bödör, PhD, Lenushka Maharaj, Janet Matthews, Rebecca Auer, MD, Sameena Iqbal, John G Gribben, Simon Joel
Journal: Blood
Blood (2012) 120 (21): 1652.
https://doi.org/10.1182/blood.V120.21.1652.1652
Published: 2012
Journal Articles

Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up

Michael Wang, M.D., Simon A. Rule, MD, Peter Martin, MD, Andre Goy, MD, Rebecca Auer, MD, Brad S. Kahl, M.D., Wojciech Jurczak, Ranjana H. Advani, MD, Jorge Enrique E Romaguera, MD, Jesse McGreivy, MD, Fong Clow, ScD, Michelle Stevens-Brogan, Lori Kunkel, MD, Kristie A. Blum, MD
Journal: Blood
Blood (2012) 120 (21): 904.
https://doi.org/10.1182/blood.V120.21.904.904
Published: 2012
Journal Articles

PI3K Inhibition with GDC-0941 Has Greater Efficacy Compared to p110δ-Selective Inhibition with CAL-101 in Mantle Cell Lymphoma and May Be Particularly Advantageous in Multiply Relapsed Patients

Sunil Iyengar, MD, Andrew J. Clear, BSc, Andrew Owen, Lenushka Maharaj, MSc, Janet Matthews, Maria Calaminici, MD, Rebecca Auer, MD, Essam Ghazaly, MD, Sameena Iqbal, John G. Gribben, MD, DSc, Simon Joel, BSc(Hons), PhD
Journal: Blood
Blood (2011) 118 (21): 1654.
https://doi.org/10.1182/blood.V118.21.1654.1654
Published: 2011